Despite minor improvements in recent years, the availability of care for people with dementia in Europe is largely inadequate, according…
Articles by Marisa Wexler, MS
People with mild-to-moderate Alzheimer’s disease treated for three weeks with sargramostim, a medication that activates the immune system,…
Cassava Sciences plans to launch two Phase 3 clinical trials evaluating the efficacy of simufilam, its investigational…
Simufilam, an investigational oral medication being developed by Cassava Sciences, improved cognition and behavior in people with Alzheimer’s…
People with Alzheimer’s disease, as well as their caregivers, are being urged — on social media and via press releases…
A newly developed technique could make it easier to measure very small concentrations of molecules, which may have implications in…
The last participant has completed the planned 24 weeks in the Phase 2 PEGASUS clinical trial, which is assessing the…
The U.S. Food and Drug Administration has given clearance for a Phase 2B clinical trial to evaluate the safety,…
An advisory arm of the U.S. Food and Drug Administration (FDA) is recommending that available clinical data on…
A first patient has been dosed in a Phase 2 trial evaluating the effects of ALZ-801 on disease-related biomarkers…